AssetMemo

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Azurity Pharmaceuticals

Specialty/reformulated branded generics (BiDil)

Privately held: no public share price · USA

Assets

(7 total)
7Total Assets
7Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
ciclesonide (Alvesco)
Approved
Glucocorticoid receptorSmall molecule
Asthma
Ferumoxytol(Feraheme)
Approved
IV iron replacement therapyOther
Chronic Kidney Disease
Isosorbide dinitrate/hydralazine(BiDil)
Approved
Hydralazine/isosorbide dinitrate (fixed combination)Small molecule
Heart Failure
Sumatriptan (Onzetra Xsail)
Approved
—Small molecule
Migraine
Sumatriptan/naproxen sodium (Treximet)
Approved
—Small molecule
Migraine
Topiramate (Eprontia)
Approved
—
Migraine
Zonisamide (Zonisade)
Approved
Voltage-gated sodium and T-type calcium channelsSmall molecule
Epilepsy

Upcoming events

Unlock with Research ↗
Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.